{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-000573","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.875537+00:00","generated_at":"2026-05-14T21:56:33.657087+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcturus Q1 net loss widens to $27M; appoints Dennis Mulroy as CFO","bullets":["Net loss of $27.0M ($0.95/diluted share), compared to $14.1M loss ($0.52/share) in Q1 2025.","Total operating expenses fell to $31.0M from $46.2M; revenue down $27.3M due to pivot from infectious disease.","Cash and equivalents $213.4M, runway beyond Q2 2028. Cash decreased $19.4M from Dec 2025.","ARCT-032 CF Phase 2 study enrollment initiated; ARCT-810 OTC deficiency gets FDA clarity for pivotal pediatric path.","Dennis Mulroy appointed CFO effective May 1, 2026; base salary $520k, options for 100k shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000573","json":"https://secwatch.observer/filing/0001193805-26-000573.json","markdown":"https://secwatch.observer/filing/0001193805-26-000573.md","text":"https://secwatch.observer/filing/0001193805-26-000573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/0001193805-26-000573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/e665435_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:56:33.657087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b0095d31ebe11b88d2f9eaef0492aab9d503a51","claim":"Arcturus Therapeutics Holdings Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/0001193805-26-000573-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ace460ed94","claim":"Dennis Mulroy was appointed as Chief Financial Officer at Arcturus Therapeutics Holdings Inc..","evidence_excerpt":"Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/0001193805-26-000573-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}